Innate Pharma (IPH) Investor Update summary

Strategic and Clinical Development Update

• Focused strategy on three priority assets: lacutamab, IPH4502, and monalizumab, with organizational streamlining and a 30% workforce reduction to align with this focus.

• Lacutamab, a first-in-class anti-KIR3DL2 antibody, has Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA and PRIME from the EU, based on strong Phase II TELLOMAK data.

• Accelerated approval for lacutamab in Sézary syndrome is targeted for 2027, with full approvals for Sézary and MF expected in 2029, following a confirmatory Phase III study.

• Monalizumab, in partnership with AstraZeneca, is in a Phase III trial (PACIFIC-9) with data expected in 2026, and IPH4502 is advancing in Phase I with early efficacy and safety data anticipated soon.

• Protocols for confirmatory Phase III trials in SS and MF have been submitted to the FDA, with no new data required for accelerated approval in SS.

Clinical Efficacy and Safety

• TELLOMAK Phase II data showed durable clinical activity, favorable safety, and quality-of-life improvements in MF and SS, supporting regulatory submissions.

• In SS patients post-mogamulizumab, lacutamab achieved a global ORR of 42.9%, median PFS of 8.3 months, and median DoR of 25.6 months.

• In MF, lacutamab induced deep responses regardless of KIR3DL2 expression, with a global clinical benefit rate of 86% and median PFS of 10.2 months.

• Quality-of-life improvements were observed in both SS and MF, with early and sustained reductions in pruritus and Skindex-29 scores.

• Safety profile was favorable, with low discontinuation rates and manageable adverse events in both SS and MF populations.

Medical and Market Landscape Insights

• CTCL is a rare disease with significant unmet needs, especially in early-stage patients who often progress to advanced disease with poor survival.

• Current systemic therapies for CTCL have limited efficacy, poor tolerability, and few durable responses, highlighting the need for new options.

• Only 25% of MF patients currently receive systemic therapy, highlighting significant market expansion potential.

• Most SS patients are managed by hematologist-oncologists, and mogamulizumab is the predominant systemic therapy in this group.

• Lacutamab aims to become the new standard of care in 2L+ MF and address high unmet needs in SS, with ambitions to expand into earlier-stage patients.